{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:31:18Z","timestamp":1791228678727,"version":"4.1.0"},"reference-count":64,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T00:00:00Z","timestamp":1437436800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:p><jats:bold><jats:italic>Disease Overview<\/jats:italic><\/jats:bold>: Mantle cell lymphoma (MCL) is a non\u2010Hodgkin lymphoma characterized by involvement of the lymph nodes, spleen, blood and bone marrow with a short remission duration to standard therapies and a median overall survival (OS) of 4\u20105 years.<\/jats:p><jats:p><jats:bold><jats:italic>Diagnosis<\/jats:italic><\/jats:bold>: Diagnosis is based on lymph node, bone marrow, or tissue morphology of centrocytic lymphocytes, small cell type, or blastoid variant cells. A chromosomal translocation t (11:14) is the molecular hallmark of MCL, resulting in the overexpression of cyclin D1. Cyclin D1 is detected by immunohistochemistry in 98% of cases. The absence of SOX\u201011 or a low Ki\u201067 may correlate with a more indolent form of MCL. The differential diagnosis of MCL includes small lymphocytic lymphoma, marginal zone lymphoma, and follicular lymphoma.<\/jats:p><jats:p><jats:bold><jats:italic>Risk Stratification<\/jats:italic><\/jats:bold>: The MCL International Prognostic Index (MIPI) is the prognostic model most often used and incorporates ECOG performance status, age, leukocyte count, and lactic dehydrogenase. A modification of the MIPI also adds the Ki\u201067 proliferative index if available. The median OS for the low\u2010risk group was not reached (5\u2010year OS of 60%). The median OS for the intermediate risk group was 51 months and 29 months for the high risk group.<\/jats:p><jats:p><jats:bold><jats:italic>Risk\u2010Adapted Therapy<\/jats:italic><\/jats:bold>: For selected indolent, low MIPI MCL patients, initial observation may be appropriate therapy. For younger patients with intermediate or high risk MIPI MCL, aggressive therapy with a cytotoxic regimen\u2009\u00b1\u2009autologous stem cell transplantation should be considered. For older MCL patients with intermediate or high risk MIPI, combination chemotherapy with R\u2010CHOP, R\u2010Bendamustine, or a clinical trial should be considered. In addition, rituximab maintenance therapy may prolong the progression\u2010free survival. At the time of relapse, agents directed at activated pathways in MCL cells such as bortezomib (NFkB inhibitor), lenalidamide (anti\u2010angiogenesis) and Ibruitinib (Bruton's Tyrosine Kinase [BTK] inhibitor) have demonstrated excellent clinical activity in MCL patients. Autologous or allogeneic stem cell transplantation can also be considered in young patients. Clinical trials with novel agents are always a consideration for MCL patients. Am. J. Hematol. 90:740\u2013745, 2015. \u00a9 2015 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.24094","type":"journal-article","created":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T16:12:59Z","timestamp":1435075979000},"page":"739-745","source":"Crossref","is-referenced-by-count":78,"title":["Mantle cell lymphoma: 2015 update on diagnosis, risk\u2010stratification, and clinical management"],"prefix":"10.1002","volume":"90","author":[{"given":"Julie M.","family":"Vose","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology University of Nebraska Medical Center  Omaha Nebraska"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,7,21]]},"reference":[{"key":"e_1_2_5_2_1","first-page":"405","article-title":"Classification of non\u2010Hodgkin's lymphomas [letter]","volume":"2","author":"Gerard\u2010Marchant R","year":"1974","journal-title":"Lancet"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0308-2261(74)80005-6"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820401)49:7<1429::AID-CNCR2820490720>3.0.CO;2-5"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_2_5_6_1","volume-title":"WHO Classification of Tumors of the Haematopietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2008"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05716.x"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22715"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-179739"},{"key":"e_1_2_5_11_1","first-page":"329","article-title":"Mantle cell lymphoma: A retrospective study of 121 cases","volume":"34","author":"Samaha H","year":"1998","journal-title":"Leukemia"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11096"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2007.04.026"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.767"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00028-X"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3419"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402272"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2230"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI61272"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2008.n.019"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm447"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-236570"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0410"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.6121"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/1096-8652(200007)64:3<190::AID-AJH9>3.0.CO;2-B"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.2.317"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.5.1288"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.133"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412096"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109097721"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200920"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_2_5_36_1","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1182\/blood.V124.21.4466.4466","article-title":"Rituximab maintenance (MR) for patients with mantel cell lymphoma (MCL)\u2014A systemic review and meta\u2010analysis of the randomized controlled trials (RCTs)","author":"Vidal L","year":"2014","journal-title":"Blood"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3883"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt070"},{"key":"e_1_2_5_40_1","doi-asserted-by":"crossref","first-page":"424a","DOI":"10.1200\/jco.2006.24.18_suppl.7511","article-title":"Mantle cell lymphoma (MCL): Induction therapy with HyperCVAD\/high dose methotrexate and cytarabine (MC)\u2009\u00b1\u2009rituximab improves results of autologous stem cell transplant in first remission","volume":"24","author":"Vose J","year":"2006","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.7055"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147025"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl127"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-370320"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-369629"},{"key":"e_1_2_5_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.100"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.9842"},{"key":"e_1_2_5_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn656"},{"key":"e_1_2_5_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-314708"},{"key":"e_1_2_5_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-189977"},{"key":"e_1_2_5_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23580"},{"key":"e_1_2_5_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.7977"},{"key":"e_1_2_5_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.226"},{"key":"e_1_2_5_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V112.11.262.262"},{"key":"e_1_2_5_57_1","first-page":"2835","article-title":"Single\u2010agent lenalidomide in patients with mangle\u2010cell lymphoma who relapsed or progressed after or were refractory to bortezomib: Phase II MCL\u2010001 (EMERGE) Study","volume":"49","author":"Goy A","year":"2013","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70200-0"},{"key":"e_1_2_5_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_2_5_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-537555"},{"key":"e_1_2_5_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.8545"},{"key":"e_1_2_5_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.2444"},{"key":"e_1_2_5_63_1","first-page":"2454","article-title":"Outcome of patients with mantle cell lymphoma undergoing autologous versus reduced\u2010intensity allogeneic transplantation","volume":"49","author":"Fenske TS","year":"2013","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-184200"},{"key":"e_1_2_5_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2275"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24094","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T13:02:31Z","timestamp":1695560551000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,21]]},"references-count":64,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.1002\/ajh.24094"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24094","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,21]]}}}